Outlook Therapeutics financials
$0.6257+0.74%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q3 '26 Jun 30 | Q2 '26 Mar 31 | Q1 '26 Dec 31 | Q4 '25 Sep 30 | Q3 '25 Jun 30 | Q2 '25 Mar 31 | Q1 '25 Dec 31 | Q4 '24 Sep 30 | Q3 '24 Jun 30 | Q2 '24 Mar 31 | Q1 '24 Dec 31 | Q4 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $8.7K | $127.4K | -$1.2M | — | $1.5M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | -$8.3K | -$21.9K | -$1.2M | — | $1.1M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | −95.0% | −17.2% | 102.5% | — | 70.8% | — | — | — | — | — | — | — |
| Operating income | -$10.8M | -$14.0M | -$13.5M | — | -$15.7M | -$12.4M | -$21.6M | -$22.9M | -$19.6M | -$18.9M | -$10.3M | -$12.5M |
| Net income | -$20.3M | -$4.5M | -$23.1M | — | -$20.2M | -$46.4M | $17.4M | $5.7M | $44.4M | -$114.3M | -$11.2M | -$13.0M |
| Net margin | −233554.9% | −3494.3% | 1909.0% | — | −1338.8% | — | — | — | — | — | — | — |
| Diluted EPS | $-0.15 | $-0.05 | $-0.38 | — | $-0.55 | $-1.50 | $0.72 | $0.27 | $-0.89 | $-8.01 | $-0.86 | $-0.35 |
| EBITDA | -$10.8M | -$14.0M | -$13.5M | $29.7K | -$15.7M | -$12.4M | -$21.6M | -$22.8M | -$19.5M | -$18.9M | -$10.3M | -$12.4M |
| Operating cash flow | -$21.0M | -$7.8M | -$14.9M | -$12.4M | -$11.9M | -$16.6M | -$11.0M | -$17.0M | -$19.5M | -$19.3M | -$13.0M | -$12.7M |
| Free cash flow | -$21.0M | -$7.8M | -$14.9M | -$12.4M | -$11.9M | -$16.6M | -$11.0M | -$17.0M | -$19.5M | -$19.3M | -$13.0M | -$12.7M |
| Diluted shares | 136.7M | 81.8M | 60.2M | 47.1M | 37.0M | 30.9M | 24.2M | 21.4M | 25.5M | 14.3M | 13.0M | 37.4M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $11.2M | $7.7M | $8.7M | $8.1M | $8.9M | $7.6M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $18.2M | $27.0M | $36.7M | $29.9M | $34.4M | $33.0M |
| Total assets | $26.2M | $21.9M | $18.2M | $18.6M | $22.4M | $19.1M |
| Total liabilities | $36.6M | $50.9M | $56.8M | $50.8M | $59.6M | $51.5M |
| Shareholders' equity | -$10.4M | -$29.0M | -$38.5M | -$32.2M | -$37.2M | -$32.5M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology